Search filters

List of works by Sibylle Loibl

13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013).

scientific article

14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts

scientific article

A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with neoadjuvant chemotherapy

article

A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies

scientific article

A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93.

scientific article published on 25 September 2007

A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).

scientific article published on 25 June 2015

A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIM

A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer

scientific article published on 18 June 2018

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

scientific article published on 28 February 2018

Adjuvant therapy in patients with breast cancer during pregnancy

scientific article published on January 2009

Advances in the treatment of advanced oestrogen-receptor-positive breast cancer

scientific article published on 6 December 2016

Adverse event management of oral mucositis in patients with breast cancer

scientific article

Analysis of PIK3CA mutations in breast cancer subtypes

scientific article

Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy ⬇️

scientific article published on April 17, 2011

Anti-epidermal growth factor receptor-antibody therapy for treatment of breast cancer

scientific article

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Ca

scientific article published on 2 August 2017

Association analysis identifies 65 new breast cancer risk loci.

scientific article published on 23 October 2017

Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis

article by Xiang Shu et al published 1 October 2018 in International Journal of Epidemiology

BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial

scientific article

BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study

article

Being Pregnant and Diagnosed with Breast Cancer

scientific article

Bendamustine in Metastatic Breast Cancer: An Old Drug in New Design

scientific article

Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades

scientific article

Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients

scientific article

Breast cancer in pregnancy

scientific article published in The Lancet

Breast cancer in pregnancy: recommendations of an international consensus meeting

scientific article published on December 2010

Can We Keep the 'PROMISE'? AGO Breast Commission: Commentary on Recent Evidence Regarding LHRH Analogues for the Preservation of Ovarian Function

scientific article published on 20 December 2011

Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study

scientific article published on 22 March 2010

Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group ⬇️

scientific article published on June 15, 2013

Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial

scientific article

Chemotherapy for 70-Year-Old Women with Breast Cancer in Germany: A Survey by the German Breast Group

scientific article published on May 2013

Classical pathology and mutational load of breast cancer - integration of two worlds

scientific article published on 20 July 2015

Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast Cancer ⬇️

scientific article published on April 24, 2008

Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials

scientific article published on 16 September 2008

Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years

scientific article published on 22 December 2017

Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast

scientific article published on April 2008

Clinical usefulness and relevance of intermediate endpoints for cytotoxic neoadjuvant therapy

scientific article

Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (A

scientific article

Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).

scientific article

Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33) ⬇️

scientific article published on October 16, 2010

Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer

scientific article published on 3 August 2015

Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy

scientific article published on 25 April 2011

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

scientific article

Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial

scientific article published on 20 April 2010

Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto.

scientific article published on 10 May 2019

Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice.

scientific article published on 14 June 2019

Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques

scientific article

Does toxicity predict efficacy? Insight into the mechanism of action of lapatinib

scientific article published on 15 September 2014

Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer Group

scientific article published in January 2010

Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70).

scientific article published on 30 March 2015

Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

scientific article

Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial

scientific article

Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

scientific article published on 10 August 2010

Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69).

scientific article published on 17 March 2017

Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature

Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis

scientific article

Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer

scientific article

Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study

scientific article published on 27 September 2013

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy

scientific article published on 29 October 2014

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

scientific article published on 17 November 2017

First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial ⬇️

scientific article published on August 24, 2010

Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor res

scientific article published on 28 September 2006

Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study

scientific article published on 23 June 2015

Genome-wide association study of germline variants and breast cancer-specific mortality

scientific article published on 21 February 2019

German Adjuvant Intergroup Node-positive Study (GAIN): A Phase III Trial Comparing Two Dose-Dense Regimens (iddEPC vs. ddEC-PwX) in High-Risk Early Breast Cancer Patients

scientific article

German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer

scientific article

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial

scientific article

Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes

scientific article

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer

scientific article published on 7 February 2013

HER2-positive breast cancer

scientific article published on 6 December 2016

Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study

scientific article

How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer?

scientific article published on 30 January 2017

Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy

scientific article published on January 2009

Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer

scientific article published on 23 October 2017

Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials

scientific article

Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer

scientific article published on 12 January 2016

Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial

scientific article

Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (GPAM) in breast cancer-link to patient survival, hormone receptor status, and metabolic profiling

scientific article published on 15 December 2011

Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial

scientific article published on 3 September 2015

Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study

scientific article published on 8 April 2008

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Brea

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

scientific article published on 29 May 2020

Investigations on the inducible and endothelial nitric oxide synthases in human breast cancer cell line MCF-7 - estrogen has an influence on e-NOS, but not on i-NOS.

scientific article published on 2 December 2005

Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment

scientific article

Ki67 measured after neoadjuvant chemotherapy for primary breast cancer

scientific article

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial ⬇️

scientific article published on January 17, 2012

Lessons from the neoadjuvant setting on how best to choose adjuvant therapies

scientific article published on October 2011

Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA).

scientific article published on 30 March 2012

Management of venous port systems in oncology: a review of current evidence

scientific article published on 09 September 2007

Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery

scientific article

Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients

scientific article published on 8 October 2013

Multicenter Phase II Study with Weekly Bendamustine and Paclitaxel as First- or Later-Line Therapy in Patients with Metastatic Breast Cancer: RiTa II Trial

scientific article published on 15 December 2011

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

scientific article published in February 2009

Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences

scientific article

NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas

scientific article published in July 2008

Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial

scientific article

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).

scientific article

Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).

scientific article published on 15 September 2017

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

scientific article

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

scientific article published in January 2012

Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data

scientific article

Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)±bevacizumab – Results of the randomised GeparQuinto study (GBG 44) ⬇️

scientific article published on March 27, 2013

Neoadjuvant clinical trials for the treatment of primary breast cancer: the experience of the German study groups

scientific article published on February 2012

Neoadjuvant treatment of breast cancer--Clinical and research perspective

scientific article published on 18 September 2015

Neoadjuvant treatment of breast cancer: maximizing pathologic complete response rates to improve prognosis

scientific article published on February 2015

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

scientific article published on 22 March 2010

Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial

scientific article published on 8 April 2008

Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer

scientific article

New Therapeutic Options for Breast Cancer during Pregnancy ⬇️

scientific article published on June 24, 2008

Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression

scientific article published on 17 March 2011

Opinions on the ASCO 2011 Annual Meeting ⬇️

scientific article published on August 19, 2011

Outcome after neoadjuvant chemotherapy in elderly breast cancer patients - a pooled analysis of individual patient data from eight prospectively randomized controlled trials

scientific article published on 26 February 2018

Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials

scientific article published on 5 September 2017

Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials

scientific article

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

Oxaliplatin and 5-fluorouracil for heavily pretreated metastatic breast cancer: a preliminary phase II study

scientific article published on August 2003

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer

scientific article published on 8 September 2014

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primar

scientific article published on March 8, 2011

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin

scientific article published on March 7, 2011

PTHrP and bone sialoprotein as prognostic markers for developing bone metastases in breast cancer patients

scientific article

Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results

scientific article

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer

scientific article

Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups ⬇️

scientific article published on July 25, 2011

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

scientific article published on 14 February 2014

Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas

scientific article

Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial

scientific article

Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer

scientific article published in January 2005

Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer

scientific article published on 18 December 2014

Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

scientific article

Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts

scientific article published on 29 August 2011

Predictive factors for response to neoadjuvant therapy in breast cancer

scientific article

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial

scientific article

Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer

scientific article

Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01).

scientific article published on 26 February 2012

Present status of adjuvant chemotherapy for elderly breast cancer patients

scientific article published on December 2012

Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history

scientific article published on 7 March 2018

Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015).

scientific article

Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study

scientific article published on 22 April 2013

Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma

scientific article

Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant "Geparquattro" trial

scientific article published on 5 July 2017

Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial

scientific article

Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial

scientific article published on 30 March 2016

RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy

scientific article published on 6 November 2012

Radiological Patterns of Brain Metastases in Breast Cancer Patients: A Subproject of the German Brain Metastases in Breast Cancer (BMBC) Registry

scientific article published on 23 September 2016

Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).

scientific article published on 30 July 2017

Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy

scientific article published on 19 August 2011

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update

scientific article published in April 2006

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.

scientific article published on 12 November 2007

Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.

scientific article

Reply to the letter to the editor 'Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study' by Daly et al.

scientific article

Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors ⬇️

scientific article published on April 19, 2011

Response-guided neoadjuvant chemotherapy for breast cancer

scientific article published on 3 September 2013

Restricted Axillary Staging in Clinically and Sonographically Node-Negative Early Invasive Breast Cancer (c/iT1-2) in the Context of Breast Conserving Therapy: First Results Following Commencement of the Intergroup-Sentinel-Mamma (INSEMA) Trial

scientific article published on February 2017

Risk assessment after neoadjuvant chemotherapy in luminal breast cancer using a clinico-molecular predictor

scientific article published on 4 April 2018

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy

scientific article published on 7 September 2016

Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning

scholarly article by F Klauschen et al published October 2018 in Seminars in Cancer Biology

Side effects of standard adjuvant and neoadjuvant chemotherapy regimens according to age groups in primary breast cancer

scientific article published on March 2013

Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells.

scientific article published on November 2004

Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA.

scientific article

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group

scientific article published on July 2016

Strategies for developing Ki67 as a useful biomarker in breast cancer

scientific article published on 14 August 2015

Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).

scientific article published on 15 March 2018

Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).

scientific article published on 21 November 2013

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.

scientific article published on 15 September 2014

Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force

scientific article published on 15 December 2015

The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group

scientific article

The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer ⬇️

scientific article published on October 29, 2012

The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial

scientific article

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy ⬇️

scientific article published on August 21, 2012

The importance of supportive care in breast cancer patients

scientific article

Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer ⬇️

scientific article published on October 18, 2012

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

scientific article published on 14 February 2019

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

scientific article

Treatment of breast cancer during pregnancy: an observational study

scientific article

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

scientific article published on 11 December 2019

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

scientific article

Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer

scientific article

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer

scientific article published on 16 November 2009

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers

scientific article published on 22 December 2014

Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy

scientific article published on 14 February 2014

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

scientific article published on 7 December 2017

Update on neoadjuvant/preoperative therapy of breast cancer: experiences from the German Breast Group

scientific article published on February 2013

Use of goserelin in the treatment of breast cancer

scientific article

Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy - Results from the multi-center SENTINA trial

scientific article published on 24 November 2016

Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy

scientific article published on 13 December 2015

Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29).

scientific article published on 17 June 2016

pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials

scientific article

Paulina is supported by:

About Paulina

Help